Entera Bio Gives Nasdaq IPO Another Shot
This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq
The financial details and timeline for the IPO were not disclosed.
Founded in 2009, Entera is a clinical stage company developing technology for the oral delivery of large molecule-based drugs, which normally degrade in the digestive system and can only be given through an IV or injection. The company focuses on treatments for osteoporosis, bone disorders and the orphan disease hypoparathyroidism, a hormone-related condition that can cause muscle contraction and nerve conduction problems.
Entera has raised $26.5 million to date according to information from Seattle-based market research company Pitchbook Data inc. Its latest funding round of $13 million, raised from undisclosed investors, was completed in October 2017.
Entera is a subsidiary of Tel Aviv-listed D.n.a Biomedical Solutions Ltd., which holds a 27% stake in the company.